ISELIN, N.J., Aug.  12, 2026  (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (&#34;Outlook Therapeutics&#34;), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™

OTLK

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics Announces Public Offering to Fund LYTENAVA US Launch

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>ISELIN, N.J., Aug.  12, 2026  (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (&amp;#34;Outlook Therapeutics&amp;#34;), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Outlook Therapeutics announced an underwritten public offering of common stock and accompanying warrants, with a 15% greenshoe option for 30 days. Proceeds will support the US commercial launch of LYTENAVA and general working capital. The dilutive potential could pressure OTLK near-term, though the financing may accelerate the US launch timeline.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Outlook to launch an underwritten public offering of common stock and warrants.</li><li>Greenshoe option up to 15% for 30 days included.</li><li>Proceeds intended for US LYTENAVA launch and working capital.</li><li>Piper Sandler and BTIG named joint bookrunners for the deal.</li><li>Offering terms subject to market conditions; no guarantee of completion.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Outlook Therapeutics, Inc. (OTLK)</strong>: Announced a public offering; potential near-term dilution for existing shareholders.</li><li><strong>Piper Sandler Companies (PIPR)</strong>: Lead bookrunner for the offering; underwriter involvement may influence near-term stock dynamics.</li><li><strong>BTIG, LLC (N/A)</strong>: Joint bookrunner; private firm serving as underwriter; indirect impact on deal dynamics.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Corporate Developments: A financing move tied to a commercialization push for LYTENAVA; demonstrates capital needs to accelerate US market entry.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Offering size and pricing are not disclosed yet, causing near-term volatility.</li><li>Underwriters Piper Sandler and BTIG are joint bookrunners.</li><li>Proceeds aim to fund US LYTENAVA launch, affecting burn rate and runway.</li><li>Dilution risk may cap near-term upside for OTLK shares.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of announcement: Aug 12, 2026.</li><li>Offering: common stock and accompanying warrants.</li><li>Greenshoe: up to 15% and 30-day overall option.</li><li>Use of proceeds: fund US LYTENAVA launch and working capital.</li><li>Underwriters: Piper Sandler and BTIG as joint bookrunners.</li><li>Shelf registration: Form S-3 333-278340; filed Mar 28, 2024; effective Apr 5, 2024.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term dilution pressure likely; longer-term upside hinges on successful US LYTENAVA launch milestones within 3–6 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">ISELIN, N.J., Aug.  12, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dsz18MRl7RbIFNc-UpdwfiW9RXS2pOLboLr5gSZrt2UgU17VlYYqAnFZ6d9yWiRgQPynKn0ENXowf7J3DVS845x0naB16y_TePcCqCueUNYv2Oodi9-IjH9ggiROrUME" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OTLK">OTLK</a>) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA&#x2122; (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock. Outlook Therapeutics also intends to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or accompanying warrants in an amount up to fifteen percent (15%) of the shares of its common stock and/or accompanying warrants offered in the public offering under the same terms and conditions. All of the securities in the proposed offering are to be sold by Outlook Therapeutics. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p>  <p align="justify">Piper Sandler and BTIG are acting as joint bookrunning managers for the proposed offering.</p>  <p align="justify">Outlook Therapeutics intends to use the net proceeds from the offering, together with existing cash and cash equivalents, to support the commercial launch of LYTENAVA&#x2122; in the United States, as well as for working capital and general corporate purposes.</p>  <p align="justify">The securities described above are being offered by Outlook Therapeutics pursuant to a "shelf" registration statement on Form S-3 (File No. 333-278340) that was originally filed with the Securities and Exchange Commission (the "SEC") on March 28, 2024, and declared effective on April 5, 2024. This proposed public offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the effective registration statement. A preliminary prospectus supplement and an accompanying prospectus related to the proposed public offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained from Piper Sandler &amp; Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com, or from BTIG, LLC , 65 East 55th Street, New York, New York 10022 or by telephone at (212) 593-7555, or by email at ProspectusDelivery@btig.com.</p>  <p align="justify">This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>  <p align="justify"><strong>About Outlook Therapeutics, Inc.</strong><br></br><br></br>Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA&#x2122; (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA&#x2122; is the only ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA&#x2122; (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.</p>  <p align="justify"><strong>Forward-Looking Statements</strong></p>  <p align="justify">This press release contains statements that may or are considered "forward-looking statements." All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "expect," "may," "on track," "plan," "potential," "target," "will," or "would" the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include statements regarding, among others, Outlook Therapeutics’ intention to conduct a public offering and sale of securities, the timing and size of the proposed public offering, the intention to grant the underwriters a 30-day option to purchase additional shares and/or warrants, the completion of the proposed public offering, the expected use of proceeds from the proposed public offering as well as the commercial launch of LYTENAVA&#x2122; in the United States and Europe, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include fluctuations in Outlook Therapeutics’ stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering, risks associated with developing and commercializing pharmaceutical product candidates, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the SEC, including Exhibit 99.1 to the Current Report on Form 8-K filed by Outlook Therapeutics with the SEC on August 12, 2026, as supplemented by subsequent reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the global geopolitical conflict, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.</p>  <p align="justify"><strong>Investor Inquiries:<br></br></strong>Jenene Thomas<br></br>Chief Executive Officer<br></br>JTC Team, LLC<br></br>T: 908.824.0775<br></br><u><a href="https://www.globenewswire.com/Tracker?data=Qq8COZOcKLVXixN8Tx-Lp0HvXJ9ujzWedC3yqDtN0-pxDp3J_s6SeX59tk4ogwrEjDE_BssAQuAQTHaKTFHuRg==" rel="nofollow" target="_blank">OTLK@jtcir.com</a></u></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwODk5NyM3NzczNjk3IzIwMjg4MjI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZWU4MTdmYmYtMjBkNy00ZjM1LWJhY2MtMTBlZDhhNDNiYzlkLTEwNDAzOTMtMjAyNi0wOC0xMi1lbg==/tiny/Outlook-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/cbff3302-f8d2-466a-beff-8c33252f9c70"><img src="https://ml.globenewswire.com/media/cbff3302-f8d2-466a-beff-8c33252f9c70/small/otlk-png.png" border="0" width="150" height="40" alt="Primary Logo"></img></a></p>

Outlook Therapeutics announced an underwritten public offering of common stock and accompanying warrants, with a 15% greenshoe option for 30 days. Proceeds will support the US commercial launch of LYTENAVA and general working capital. The dilutive potential could pressure OTLK near-term, though the financing may accelerate the US launch timeline.

News insight

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

AI summary

Sentiment rationale

Key facts

Corporate Developments